T-1095 

T-1095 is a selective and orally active Na⁺-glucose cotransporter (SGLT) inhibitor with IC₅₀s of 22.8 µM and 2.3 µM for human SGLT1 and SGLT2, respectively. T-1095 can be used for diabetes research^[1].

T-1095 is absorbed into the circulation via oral administration, is metabolized to the active form, T-1095A, and suppresses the activity of SGLTs in the kidney^[1].
Orally administered T-1095 (3-30 mg/kg) increases urinary glucose excretion in diabetic animals, thereby decreasing blood glucose levels^[1].
With long-term T-1095 (0.01% or 0.1% T-1095 mixed diet; for 28 days) treatment, both blood glucose and HbA1c levels were reduced in streptozotocin (STZ)-induced diabetic rats and yellow KK mice. In addition, there was amelioration of abnormal carbohydrate metabolism, i.e., hyperinsulinemia and hypertriglyceridemia, and of the development of microalbuminuria, in yellow KK mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

516.49

C₂₆H₂₈O₁₁

209746-59-8

O=C(C(C(O)=C1)=C(C=C1C)O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]([C@H]2O)COC(OC)=O)CCC3=CC=C4C(C=CO4)=C3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. A Oku, et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999 Sep;48(9):1794-800.  [Content Brief]